Literature DB >> 22180062

Serum ghrelin is inversely associated with risk of subsequent oesophageal squamous cell carcinoma.

Gwen Murphy1, Farin Kamangar, Demetrius Albanes, Frank Z Stanczyk, Stephanie J Weinstein, Philip R Taylor, Jarmo Virtamo, Christian C Abnet, Sanford M Dawsey, Neal D Freedman.   

Abstract

BACKGROUND: Gastric atrophy, as determined by a low serum pepsinogen I:II ratio, may be associated with an increased risk of oesophageal squamous cell carcinoma (OSCC). Ghrelin, a hormone which, is also produced in the gastric fundic glands may be a marker of gastric atrophy, but its association with OSCC is not known.
METHODS: To examine the relationship between baseline serum ghrelin concentration and subsequent risk of OSCC, the authors conducted a nested case-control study within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) study. 82 cases of OSCC were matched (1:1) by age and date of blood draw to controls from the ATBC study. Serum ghrelin was measured by radioimmunoassay. ORs and 95% CIs were calculated using conditional logistic regression with adjustment for potential confounders.
RESULTS: For individuals in the lowest quartile of serum ghrelin, compared to those in the highest, the multivariate OR of subsequent OSCC was 6.83 (95% CI 1.46 to 31.84). These associations were dose dependent (p value for trend =0.005 for both), and independent of the effects of low pepsinogen I:II ratio and Helicobacter pylori infection. The significance of these associations remained even for individuals developing OSCC up to 10 years after baseline ghrelin measurement, although they become attenuated after 10 years.
CONCLUSION: Lower baseline concentrations of serum ghrelin were associated with an increase in risk of OSCC. Further studies are needed to confirm this finding in other populations and to explore the role of ghrelin in the aetiology of OSCC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22180062      PMCID: PMC3462270          DOI: 10.1136/gutjnl-2011-300653

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  37 in total

1.  Serum pepsinogens and Helicobacter pylori in relation to the risk of esophageal squamous cell carcinoma in the alpha-tocopherol, beta-carotene cancer prevention study.

Authors:  Michael B Cook; Sanford M Dawsey; Lena Diaw; Martin J Blaser; Guillermo I Perez-Perez; Christian C Abnet; Philip R Taylor; Demetrius Albanes; Jarmo Virtamo; Farin Kamangar
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-20       Impact factor: 4.254

Review 2.  The effects of ghrelin on inflammation and the immune system.

Authors:  Dolgor Baatar; Kalpesh Patel; Dennis D Taub
Journal:  Mol Cell Endocrinol       Date:  2011-04-30       Impact factor: 4.102

Review 3.  Ghrelin and cancer.

Authors:  Lisa Chopin; Carina Walpole; Inge Seim; Peter Cunningham; Rachael Murray; Eliza Whiteside; Peter Josh; Adrian Herington
Journal:  Mol Cell Endocrinol       Date:  2011-05-25       Impact factor: 4.102

Review 4.  Gastric atrophy and risk of oesophageal cancer and gastric cardia adenocarcinoma--a systematic review and meta-analysis.

Authors:  F Islami; P Sheikhattari; J S Ren; F Kamangar
Journal:  Ann Oncol       Date:  2010-09-22       Impact factor: 32.976

5.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.

Authors:  Jacques Ferlay; Hai-Rim Shin; Freddie Bray; David Forman; Colin Mathers; Donald Maxwell Parkin
Journal:  Int J Cancer       Date:  2010-12-15       Impact factor: 7.396

Review 6.  Endocrine impact of Helicobacter pylori: focus on ghrelin and ghrelin o-acyltransferase.

Authors:  Penny L Jeffery; Michael A McGuckin; Sara K Linden
Journal:  World J Gastroenterol       Date:  2011-03-14       Impact factor: 5.742

7.  The relationship between serum ghrelin and the risk of gastric and esophagogastric junctional adenocarcinomas.

Authors:  Gwen Murphy; Farin Kamangar; Sanford M Dawsey; Frank Z Stanczyk; Stephanie J Weinstein; Philip R Taylor; Jarmo Virtamo; Christian C Abnet; Demetrius Albanes; Neal D Freedman
Journal:  J Natl Cancer Inst       Date:  2011-06-21       Impact factor: 13.506

Review 8.  Expression, regulation and biological actions of growth hormone (GH) and ghrelin in the immune system.

Authors:  Naoki Hattori
Journal:  Growth Horm IGF Res       Date:  2009-01-13       Impact factor: 2.372

Review 9.  Ghrelin's role on gastrointestinal tract cancer.

Authors:  Dimitrios Nikolopoulos; Stamatis Theocharis; Gregory Kouraklis
Journal:  Surg Oncol       Date:  2009-03-28       Impact factor: 3.279

Review 10.  Environmental causes of esophageal cancer.

Authors:  Farin Kamangar; Wong-Ho Chow; Christian C Abnet; Sanford M Dawsey
Journal:  Gastroenterol Clin North Am       Date:  2009-03       Impact factor: 3.806

View more
  11 in total

1.  Associations of diabetes mellitus, insulin, leptin, and ghrelin with gastroesophageal reflux and Barrett's esophagus.

Authors:  Joel H Rubenstein; Hal Morgenstern; Daniel McConell; James M Scheiman; Philip Schoenfeld; Henry Appelman; Laurence F McMahon; John Y Kao; Val Metko; Min Zhang; John M Inadomi
Journal:  Gastroenterology       Date:  2013-08-30       Impact factor: 22.682

Review 2.  Energy balance and gastrointestinal cancer: risk, interventions, outcomes and mechanisms.

Authors:  Cornelia M Ulrich; Caroline Himbert; Andreana N Holowatyj; Stephen D Hursting
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-11       Impact factor: 46.802

Review 3.  Etiology, cancer stem cells and potential diagnostic biomarkers for esophageal cancer.

Authors:  Kuancan Liu; Tingting Zhao; Junkai Wang; Yunyun Chen; Rui Zhang; Xiaopeng Lan; Jianwen Que
Journal:  Cancer Lett       Date:  2019-05-21       Impact factor: 8.679

4.  Serum ghrelin is associated with risk of colorectal adenocarcinomas in the ATBC study.

Authors:  Gwen Murphy; Amanda J Cross; Sanford M Dawsey; Frank Z Stanczyk; Farin Kamangar; Stephanie J Weinstein; Philip R Taylor; Satu Männistö; Demetrius Albanes; Christian C Abnet; Neal D Freedman
Journal:  Gut       Date:  2017-08-16       Impact factor: 23.059

Review 5.  Clinical application of ghrelin administration for gastric cancer patients undergoing gastrectomy.

Authors:  Shuji Takiguchi; Akihiro Takata; Kohei Murakami; Yasuhiro Miyazaki; Yoshitomo Yanagimoto; Yukinori Kurokawa; Tsuyoshi Takahashi; Masaki Mori; Yuichiro Doki
Journal:  Gastric Cancer       Date:  2013-09-20       Impact factor: 7.370

Review 6.  Helicobacter pylori infection and esophageal cancer risk: an updated meta-analysis.

Authors:  Fa-Jun Xie; Yi-Ping Zhang; Qiu-Qing Zheng; Hong-Chuan Jin; Fa-Liang Wang; Ming Chen; Lan Shao; De-Hong Zou; Xin-Min Yu; Wei-Min Mao
Journal:  World J Gastroenterol       Date:  2013-09-28       Impact factor: 5.742

Review 7.  Is there an effect of ghrelin/ghrelin analogs on cancer? A systematic review.

Authors:  Sakine Sever; Donna L White; José M Garcia
Journal:  Endocr Relat Cancer       Date:  2016-09       Impact factor: 5.678

Review 8.  Attribution of Ghrelin to Cancer; Attempts to Unravel an Apparent Controversy.

Authors:  Saeed Soleyman-Jahi; Fatemeh Sadeghi; Amin Pastaki Khoshbin; Leila Khani; Venus Roosta; Kazem Zendehdel
Journal:  Front Oncol       Date:  2019-10-16       Impact factor: 6.244

9.  Serum ghrelin and esophageal and gastric cancer in two cohorts in China.

Authors:  Natalie R Pritchett; Marlena Maziarz; Xiao-Ou Shu; Farin Kamangar; Sanford M Dawsey; Jin-Hu Fan; Bu-Tian Ji; Yu-Tang Gao; Yong-Bing Xiang; You-Lin Qiao; Honglan Li; Gong Yang; Shao-Ming Wang; Frank Z Stanczyk; Wong-Ho Chow; Hormuzd A Katki; Wei Zheng; Qing Lan; Neal D Freedman; Nat Rothman; Christian C Abnet; Gwen Murphy
Journal:  Int J Cancer       Date:  2019-08-12       Impact factor: 7.316

10.  Serum ghrelin; a new surrogate marker of gastric mucosal alterations in upper gastrointestinal carcinogenesis.

Authors:  Alireza Sadjadi; Abbas Yazdanbod; Yeong Yeh Lee; Majid Boreiri; Fatemeh Samadi; Behrooz Z Alizadeh; Farhad Islami; Valerie Fyfe; Masoud Babaei; Mohammad J Namazi; James J Going; Masoud Sotoudeh; Geertruida H de Bock; Reza Malekzadeh; Mohammad H Derakhshan
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.